- Oops!Something went wrong.Please try again later.
CHICAGO & CAMBRIDGE, Mass., October 28, 2021--(BUSINESS WIRE)--Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced presentations at the following scientific conferences during the month of November:
Title: "Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain"
Presented by: Bart Anderson, Senior Director, R&D
Date: November 16, 2021
Time: 8:45am CET / 1:45am U.S. CST
Neuroscience 2021 (The Society for Neuroscience)
Poster 1: "Spherical Nucleic Acids Targeting FXN Induce Frataxin Expression in Models of Friedreich’s Ataxia"
Presented by: Grant Corbett, Group Lead, Neuroscience
Poster 2: "Biodistribution of Spherical Nucleic Acids in the Mouse CNS Following ICV, ICM and IT Delivery"
Presented by: Lauren Moore, Senior Scientist, Neuroscience
November 8-11, 2021
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. www.exicuretx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005075/en/